Page last updated: 2024-10-20

selenious acid and Cancer of Ovary

selenious acid has been researched along with Cancer of Ovary in 4 studies

Selenious Acid: A selenium compound with the molecular formula H2SO3. It used as a source of SELENIUM, especially for patients that develop selenium deficiency following prolonged PARENTERAL NUTRITION.

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19901 (25.00)18.7374
1990's1 (25.00)18.2507
2000's0 (0.00)29.6817
2010's2 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Song, M1
Kumaran, MN1
Gounder, M1
Gibbon, DG1
Nieves-Neira, W1
Vaidya, A1
Hellmann, M1
Kane, MP1
Buckley, B1
Shih, W1
Caffrey, PB2
Frenkel, GD2
Rodriguez-Rodriguez, L1
Liu, J1
Li, J1
Zhang, JF1
Xin, XY1
Ohkawa, K1
Tsukada, Y1
Dohzono, H1
Koike, K1
Terashima, Y1

Trials

1 trial available for selenious acid and Cancer of Ovary

ArticleYear
Phase I trial of selenium plus chemotherapy in gynecologic cancers.
    Gynecologic oncology, 2018, Volume: 150, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cell Lin

2018

Other Studies

3 other studies available for selenious acid and Cancer of Ovary

ArticleYear
Combination of fenretinide and selenite inhibits proliferation and induces apoptosis in ovarian cancer cells.
    International journal of molecular sciences, 2013, Nov-04, Volume: 14, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspase 3; Cell Line, Tumor; Cell Prolife

2013
Selenite cytotoxicity in drug resistant and nonresistant human ovarian tumor cells.
    Cancer research, 1992, Sep-01, Volume: 52, Issue:17

    Topics: Cell Adhesion; Cell Division; Cell Survival; Drug Resistance; Female; Humans; In Vitro Techniques; O

1992
The effects of co-administration of selenium and cis-platin (CDDP) on CDDP-induced toxicity and antitumour activity.
    British journal of cancer, 1988, Volume: 58, Issue:1

    Topics: alpha-Fetoproteins; Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Respons

1988